Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P0
Near historical low
vs 5Y Ago
-0.3x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-9.68%
2024-7.57%
2023-8.48%
2022-7.99%
202140.33%
202035.73%
2019109.87%
2018161.23%
201775.39%
201667.36%